Neurofibromatosis Type 1 (NF1)
4 clinical trials · Condition
◉ Watch Neurofibromatosis Type 1 (NF1)
| Record | Firm | Date |
|---|---|---|
| PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas (NCT06961565) | Pasithea Therapeutics Corp. | 2025-05-30 |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (NCT03962543) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 2019-09-29 |
| Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) (NCT01968590) | University of Utah | 2017-08-16 |
| Precision Medicine for Neurocutaneous Syndromes in Western China (NCT07327164) | West China Hospital | 2000-01-01 |
Track Neurofibromatosis Type 1 (NF1) automatically
Every clearance here is in the API, with alerts when new ones post.